

## Description

**MEDICAL DEVICES HAVING ANTIMICROBIAL PROPERTIES**5 Technical Field

The present invention relates to microbial-resistant medical devices and, more particularly, this invention relates to a voice prosthesis having a valve which retards growth of microbial organisms.

10

10 Background of the Invention

Medical devices, particularly synthetic resin prosthetic devices which are used in environments where micro-organisms such as fungi or yeast and/or bacteria are actively growing, can become covered with a biofilm colonized layer to the point where the function of the device is impaired. After growth of the biofilm microbial layer, filaments can grow and descend into the body or wall of the polymeric device and detrimentally affect its physical properties until the device no longer functions. The fouled device must be cleaned or discarded.

20 Whenever a prosthesis is in contact with moisture in a warm, dark environment, the surfaces are subject to microbial growth, usually containing a predominant amount of *Candida* usually mixed with bacteria. The microbial growth can interfere with the functioning of the prosthesis, requiring removal of the prosthesis for disposal or cleaning. The microbial growth is a persistent problem in the management and care of patients who have had their larynx removed and utilize a voice prosthesis since the prosthesis is exposed to a non-sterile, humid, warm, nutrient rich environment.

25 30 There are several options for restoring speech to patients who have had their larynx removed. One procedure is to surgically create a puncture or fistula between the trachea and the esophagus. A tracheoesophageal voice prosthesis containing a one-

5 way valve such as a BLOM-SINGER® voice prosthesis is inserted into  
the tracheoesophageal fistula. The one-way valve protects the  
airway during swallowing but opens under positive pressure from  
the trachea. The voice prosthesis, thus, permits a patient to  
10 divert air from the lungs into the esophagus and out through the  
mouth. Speech is created during passage of air through the upper  
part of the esophagus.

The prosthesis maintains the fistula open, transfers air from  
the trachea to the esophagus for voice production and prevents  
esophageal leakage into the trachea during swallowing. The  
15 oral cavity which extends into the throat has a high microbial  
population. However, the prosthesis being in contact with mois-  
ture in a warm, dark, nutrient rich environment is subject to  
growth of commonly found micro-organisms, typically Candida on the  
20 valve and the retaining flange. The microbial attack is currently  
being studied. The microbial attack organisms and sequence of  
events are quite complex and are still undetermined. The  
microbial growth on and into the soft silicone resin can interfere  
with function of the valve and can cause the flange to wrinkle and  
the valve to leak. The fouled device must be cleaned or discarded  
25 and replaced with a new device.

One type of current low pressure voice prosthesis can be  
removed by the patient every few days and can be replaced with a  
clean prosthesis. The removed prosthesis is soaked in hydrogen  
peroxide to sterilize and clean the valve and flange. Some  
30 patients however, have difficulty managing frequent removal and  
reinsertion of the prosthesis. Others, who are physically  
handicapped are not able to remove, sterilize, or reinsert the  
prosthesis.

A longer dwelling, low pressure voice prosthesis has been  
35 developed that can remain in place in the tracheoesophageal  
fistula for many weeks or months, depending on the patient and  
conditions of use. The patient can confidently use the prosthesis  
for longer periods. The longer dwelling voice prosthesis is not

removable by the patient. Trips to a health care specialist to remove and replace the prosthesis are greatly extended providing increased comfort and lower cost to the patient.

Another type of soft voice prosthesis includes a rigid stiffening ring 14 inserted into a groove in the soft body of the prosthesis. Though the ring stiffens the body adjacent the valve it does not prevent distortion of the body by muscular movement or distortion of the valve by growth of yeast.

U.S. Patent No. 5,578,083 issued November 26, 1996, discloses the use of a stiff cartridge to support the soft silicone prosthesis and to provide a seat for the valve. However, microbial growth still proceeds to a point at which the valve can not be reliably sealed.

Microbial growth on the valve can also cause distortion of the shape of the valve or form wrinkles in the body of the valve which prevents the valve from closing. Leaking also appears to be due to distortion of the valve body adjacent to the seat of the valve and to microbial growth on the seat. Forming the valve with an arcuate dome shape increased resistance to folding or bending of the valve. However, some valves still leaked after extended placement in a fistula.

### List of Prior Art

<u>Patent No.</u>	<u>Patentee</u>
3,932,627	Margraf
4,054,139	Crossley
4,483,688	Akijama
4,563,485	Fox, Jr. et al.
4,581,028	Fox, Jr. et al.
4,603,152	Laurin, et al.
4,612,337	Fox, Jr. et al.
4,615,705	Scales et al.
5,019,096	Fox, Jr. et al.
5,567,495	Modak et al.
5,624,704	Darouiche et al.
5,772,640	Modak et al.
5,902,283	Darouiche et al.
6,083,208	Modak et al.
6,106,505	Modak et al.

Statement of Prior Art

10 Margraf discloses the use of a silver-heparin-allantoin complex to a form non-thrombogenic, self sterilizing surface on prosthetic valves or arterial grafts. The complex can be coated or impregnated into the surface of the valve or graft.

15 Crossley coats the surface of an urinary tract catheter with Ag or Ag compounds by dispersing silver or its compound in resin. The surface is abraded to expose the silver material. The coating contains 10% by weight of silver (col 4, line 10). The coating can be extremely thin such as those deposited by electroless deposition (col 4, lines 16-18).

20 Fox, Jr. et al., 4,563,485 discloses use of silver norfloxacin or silver perfloxacin to render muscular graft prosthesis formed from resins such as silicone infection resistant.

25 Fox, Jr. et al., utilizes silver metal salts of sulfonamides or other antimicrobials for the same purpose.

30 Fox, Jr. et al., discloses and claims a method of preparing an infection resistant material by solvent impregnation of the material with a silver salt and another compound and reaction in situ to form a silver salt.

35 Scales et al., provides a bioerodible silver coating on the surface of endoprosthetic orthopaedic implants to render the surface antimicrobial.

40 Fox, Jr. et al., discloses the use of a complex of a silver salt and chlorhexidine to add antimicrobial properties to biomedical polymers such as silicones.

Laurin, et al. discloses mixing an oligodynamic material such as a salt of silver, gold, platinum, copper or zinc with a resin to form an antimicrobial coating for catheters.

Akijama coats an oligodynamically active silver, gold or copper salt on the periphery of a tubular catheter.

5           Modak et al. and Darouiche et al. discloses the use of  
triclosan to silicone medical devices such as catheters to inhibit  
microbial growth. By coating the agent onto the surface of the  
device or soaking the device in swelling agent and then in a  
10          solution containing triclosan to introduce triclosan into the  
device.

15          When soft prostheses were compounded with antimicrobial  
agents such as silver compounds at a level which resists growth of  
microorganisms, it was discovered that the prosthesis was ir-  
ritating to and/or toxic to tissue in contact with the prosthesis.

15          Statement of the Invention

20          It has been discovered in accordance with the present  
invention that antimicrobial agents can be compounded into parts  
of a prosthetic that are not in contact with tissue. The  
25          antimicrobial parts will be free of microbial growth for an  
extended period which contributes to longer use of the prosthesis  
in vivo. For example, the valve in most voice prostheses is not  
in contact with tissue. It is only in intermittent contact with  
body fluids. The same is true of the inside surface of the  
30          tubular prosthesis and/or the facial and inside surfaces of rings  
or cartridges present to reinforce the soft body of a prosthesis.

35          By adding an amount of microbial agent effective to resist growth  
onto or into the valve, ring or cartridge it is found that  
microbial growth is delayed for a significant period without any  
evidence of irritation or toxicity to the tissue.

35          It also has been discovered that microbial growth on bio-  
compatible polymers such as silicone elastomers is complex. It is  
very difficult to duplicate the microbial growth in vivo.  
Furthermore, the microbes appear to be patient dependent. The  
growth proceeds through several stages as follows:

1. Deposition of a biofilm
2. Feeding and attack by microbes (bacteria origin)
3. Feeding and attack by yeast

5        The microbial growth on the surface of the polymer can be  
-        impeded by breaking the chain of any of the three events.

10       An antimicrobial surface on a prosthetic device can be  
-        provided by soaking the surface of the device in solution  
containing an agent that reacts with or interferes with the  
biofilm, microbes or yeast. Coating the surface of the device  
with a layer of the agent, grafting the agent onto the surface,  
treating the surface such as with high energy beams to render the  
surface antimicrobial and dispersing the agent within the wall of  
the device at a level at which the surface is antimicrobial are  
15       other methods of providing an antimicrobial surface.

20       The body of the prosthesis can be formed of a mixture of  
dissimilar materials such as elastomers or can be formed of layers  
of different elastomers. Reduced tendency of microbes to adhere  
to the surface of silicone elastomers can be provided by coating  
the surface of a silicone elastomer with a layer of polyurethane  
elastomer. The rate of leaching a dispersed antimicrobial  
material from an elastomer can be controlled by coating the  
surface of the elastomer with a layer impermeable to the  
antimicrobial material such as a phenyl silicone elastomer in the  
25       case of a silicone elastomer. The leach rate of the outer layer  
can be controlled by forming pores of controlled size in or  
apertures through the layer.

30       The isolation of the valve from tissue is enhanced by  
recessing the valve forward of the rearward edge of the prosthesis  
and/or forward of a flange which seats the prosthesis in a  
tracheoesophageal fistula.

35       The body of the prosthesis may have some antimicrobial  
properties as long as the surface of the body is not toxic to  
tissue. For example, the body can be formed of a polyurethane  
polymer which resists attachment of a biofilm or a microbial  
layer.

      The antimicrobial agent can also be compounded by dispersion  
into the raw material. For example, silicone elastomer can

5 contain up to 100 phr of an antimicrobial agent such as silver or  
silver compounds such as silver oxide suitably about 5 up to less  
than 50 phr of silver oxide. Other suitable antimicrobial com-  
pounds toxic to tissue can be used in the non-tissue contact  
10 regions such as gold, platinum, copper, zinc metal powder or  
oxides and salts thereof.

A metal coating that retards microbial growth can be  
deposited on a silicone surface by ion deposition in a vacuum  
chamber (SPIRE process) as disclosed in U.S. Patent Nos. 5,474,797  
15 and 5,520,664, the disclosures of which are incorporated herein by  
reference. Suitable metals are platinum, iridium, gold, silver,  
mercury, copper, iodine, and alloys, compounds and oxides thereof.

Preferred antimicrobial agents are organic antimicrobial  
agents that can be dispersed throughout the raw material  
preferably a food grade preservative such as an aromatic  
20 carboxylic acid or C<sub>1</sub> to C<sub>9</sub> ester thereof such as butyl paraben  
butyl p-hydroxy benzoate or an alkene carboxylic acid salts such  
as alkali metal sorbate salt or a halohydroxy aromatic ether such  
as triclosan (2,4,4'-trichloro-7'hydroxydiphenyl ether).

The agents can be dispersed throughout the raw material by  
25 milling a dry powder into liquid resin before curing by  
predissolving in minimum amount of solvent and then mixing or  
milling the solution into the liquid resin or heating the agent  
above its melting temperature but below its decomposition  
30 temperature and mixing the molten material with the liquid resin  
before molding. The agents were chosen to be sufficiently robust  
to survive the molding process.

35 Valves and cartridges for voice prosthesis have been  
compounded with a dispersion of antimicrobial agents and were  
subjected to in vitro and in vivo testing. The valves and  
cartridges are found to exhibit significant inhibition of  
microbial growth.

These and many other features and attendant advantages of the  
invention will become apparent as the invention becomes better

5 understood by reference to the following detailed description when considered in conjunction with the accompanying drawings.

Brief Description of the Drawings

10 Figure 1 is a schematic view of a voice prosthesis installed in a tracheoesophageal fistula;

Figure 2 is a view in section of an assembly of the valve, cartridge and body of an embodiment of the voice prosthesis of the invention;

15 Figure 2a is an enlarged sectional view of the valve securing means shown in Figure 2 for purposes of clarity;

Figure 3 is a side view in elevation of the valve shown in Figure 2;

20 Figure 4 is a front view in elevation of the valve shown in Figure 2;

Figure 5 is a rear view in elevation of the cartridge shown in Figure 2;

25 Figure 6 is a view in section taken along line 6-6 of Figure 5;

Figure 7 is a view in section taken along line 7-7 of Figure 6;

30 Figure 8 is a bottom view in elevation of the cartridge illustrated in Figure 2.

Figure 9 is a top view in elevation of the prosthesis illustrated in Figure 9; and

35 Figure 10 is a view in section taken along line 10-10 of Figure 9.

Detailed Description of the Invention

35 The invention will be illustrated by a long-dwelling voice prosthesis with hard cartridge and a soft body voice prosthesis, though it is applicable to any prosthetic or medical device

5 disposed in a body cavity having an environment conducive to  
growth of micro-organisms such as *Candida Albicans*.

10 Referring now to Figures 1 and 8-9, a voice prosthesis 10 is  
shown inserted into a fistula 62 with the front flange 14 engaging  
the outer wall 64 of the trachea and the rear flange 16 engaging  
15 the wall 66 of the esophagus. The body 12 of the prosthesis 10  
prevents the fistula 62 from closing. The body 12 and flanges 14,  
16 are formed of an elastomer material which is non-toxic to  
tissue. The prosthesis 10, 310 also contains a valve 60, 360 as  
shown in Figures 2-4 and Figures 8, 9 which has an antifungal  
20 surface 215, 315 toxic to tissue. The valve 60, 360 is preferably  
separately molded and has a flap 20 or 2 posts 320 which are  
attached to the prosthesis 10, 310. In the soft prosthesis 310,  
25 the posts 320 are received in cavities 322 in the body and secured  
thereto by potting with a biocompatible adhesive such as RTV. The  
valve could also be mounted in a rigid sleeve attached to the  
distal end of the cartridge.

20 Referring again to Figures 2-4, a long dwelling prosthesis  
210 can further contain an internal, rigid cartridge 212 which  
reinforces the body 214 of the soft prosthesis as shown in Figures  
25 2-8 and as disclosed in U.S. Patent No. 5,578,083 the disclosures  
of which are expressly incorporated herein by reference.

30 Referring particularly now to Figures 2 and 2a, a preferred  
voice prosthesis 210 is formed of a tubular body 214, a hollow,  
rigid cartridge 212 received in a channel 213 through the body 214  
and a flapper valve 215 mounted on the rear face 217 of the  
cartridge 212.

35 A front tracheal flange 216 and a rear retention esophageal  
flange 219 are connected to the ends of the body 214. A flexible  
tab 218 can be attached to the front flange 216. The tab 218 can  
contain an aperture 221 which can be connected to an insertion  
tool, not shown. The body 214, front flange 216 and rear flange  
219 are preferably a single molded, unitary structure formed from  
a biocompatible elastomer such as silicone resin, suitably a 50

5 durometer, medical grade, silicone elastomer. Since the resin is  
- transparent and the prosthesis structure is small, the prosthesis  
is difficult to visualize and handle. Therefore, the molding  
10 resin generally, but not always, can contain a small amount, from  
0.1 to 0.5% of a biocompatible pigment to aid in seeing the  
device. The pigment can be a heavy metal salt such as barium sul-  
fate. The cartridge 212 can be formed of an inert, self-  
lubricating thermo plastic polymer, a fluorinated resin such as  
KYNAR, a semi-crystalline, low molecular weight polymer of  
15 vinylidene fluoride, such as TEFLON (polytetrafluoroethylene) or a  
polyalkylene resin such as polyethylene or polypropylene.

The tubular body 214 has a first section 222 having a wall  
223 of a first thickness, a central section 224 having a wall 227  
of a greater thickness and a third wall section 226 having a wall  
229 of reduced thickness. The central wall section 224 forms a  
20 cylindrical boss 231 which is received in an annular channel 228  
formed in the outer wall of the cartridge 212.

The hollow cartridge 212 has a front flange 240, a rear  
flange 244 forming a central channel 242 between the flanges 240,  
244. The cartridge 212 is assembled with the body 214 by  
25 inserting the front flange 240 of the cartridge 212 into the rear  
opening 245 of the body 214 and forcing it through the central  
channel 213 of the body compressing the boss 231 until the front  
flange 240, seats against the end wall 248 of the boss 231 and the  
rear flange 244 seats against the rear wall 250 of the boss 231.

30 Referring now to Figures 3 and 4, the rear flange 244 has a  
horizontal slot 243 for receiving a tab 232 mounted on the front  
face of the valve 60 which communicates with an enlarged recess  
245. The remaining volume in the recess 245 can be filled with  
35 biocompatible adhesive such as a silicone adhesive. Preferably,  
the tab 232 contains a bulbous end 261 which seats in the recess  
245. The rear face 262 of the rear flange 244 can be angled to  
the vertical in order to preload the valve 60. Usually the angle  
is from 1 to 20 degrees, preferably 3 to 10 degrees.

5 Referring further to Figures 3 and 4, the flapper valve 60 has a round segment 230 connected to an attachment flap 256. A live hinge 234 in the form of a score line separates the segment 230 from the flap 256. A tab 232 is provided on the flap 256 for attaching the valve 60 to the body of the cartridge 212.

10 The hinge is located adjacent the lower, recessed portion of the rear face of the flange 244 which preloads the valve 60. The valve 60 is further strengthened by the increased thickness of the dome-shaped rear face 280 of the round segment 230. Leakage of the valve is further decreased due to the seating of the valve element 60 on the hard, smooth outer surface 217 of the rear flange 244 of the cartridge.

15 In order to assure that the rear flange 219 of the body 214 is fully seated on the esophageal wall surrounding a fistula, a narrow opaque ring 282 can be attached to or molded into the rear flange 219 as disclosed in U.S. Patent No. 5,480,432 on January 2, 1996, the disclosure of which is expressly incorporated herein by reference. An opaque pattern can also be provided by depositing opaque dots such as tantalum on the flange. The ring 282 has a width at least 10% the diameter of the rear flange usually from 20 10% to 50% the diameter of the annular rear flange. Usually the rear flange has a diameter of about 0.5 inch and the ring has a width of about 0.05 to 0.10 inch. The ring 282 preferably has an outer perimeter coincident with that of the rear flange 219 so that folds anywhere on the rear flange will be detected by the 25 displayed image of the ring 282. The ring is preferably formed of the same flexible resin as the rear flange but contains an amount of radiopaque pigment such as barium sulfate sufficient to render the ring opaque to X-rays. Usually the pigment is present in an amount from at least 5% to 35%, generally around 20% by weight.

30 35 The front flange 240 of the cartridge 212 can have a bevel 241 so that it is easier to move the front flange 240 past the boss 231 on the body 214 of the device.

The body 214 can also contain a recess 220 placed forward of

5 the rear flange 219 to further protect the valve from failing by further isolating the valve from contacting tissue. A hood may also be provided rearward of the flange 219.

10 Referring more particularly now to Figure 5-8 the front flange 240 and the rear flange 244 of the hard cartridge 212 may contain key shaped slots 243, 245 which cooperate with a key bar 265 on the bottom of the soft tubular body 214. The rear end 267 of the key bar 265 bears against the bulbous end 261 of the flexible tab 256.

15 Providing a microbial resistant valve according to the invention may eliminate or reduce the need to utilize a thick domed valve and a thicker, stiffer rear flange. Since the growth of a thick biofilm layer will be inhibited, warping of the valve is reduced or eliminated. The microbial resistant surface can be provided by coating or laminating a layer of microbial resistant polymer onto the exposed surfaces of the valve or by dispersing a microbial agent such as metal, metal oxide or salt or organic antimicrobial agent into the biocompatible resin.

20

25 The microbial resistant surface is formed of a polymer having a minimum thickness to inhibit microbial growth. The thickness of the coating can be as small as a monolayer and generally is at least 0.005 inches in thickness and usually from at least 0.01 to 0.3 inches in thickness. A layer of microbial resistant polymer can be coated onto the surface from solutions or dispersions of the polymer, can be formed on the surface by polymerization of monomers in situ, or by curing liquid prepolymers on the surface 30 of the prosthesis. The layers can also be laminated to the surface by adhesive or by heat. In the case of certain elastomeric polymers that have the appropriate physical properties for use as a valve, the valve may be formed from the microbial 35 resistant polymer.

The preferred manner of providing a surface resistant to microbial growth is to disperse the agent in the resin forming the portion of the device not in direct contact with body tissue. The

5 agent can be inorganic such as a salt or oxide of silver, gold, platinum, zinc or copper, preferably silver oxide or organic materials soluble or dispersible in the resin forming the valve or the cartridge such as hydroxy aromatic carboxylic acids, esters thereof or halogenated phenols. The agent is present in the resin  
10 or at least in a surface layer in an amount effective to deter microbial growth and at a concentration that can be toxic to tissue. The portions of the device in contact with tissue can contain a much lower concentration of the microbial agent at a level non-toxic and non-irritating to tissue.

15 For example, in the case of silver oxide, the concentration of silver oxide effective to deter growth of microbial biofilm is from 1 to 50 phr, preferably 8 to 25 phr. The body of the device which is in direct contact with tissue can be compounded to include from 0.1 to 2 phr, preferably 0.5 to 1.0 phr of silver  
20 oxide.

25 The following experiments were conducted to determine the biocompatibility requirements of compounding silver oxide into bodies and valves of voice prosthesis at different concentrations and of coating the outside surfaces of a voice silicone elastomer prosthesis and valve with vaporized metal coatings by the SPIRE® process. The silver oxide was dispersed in the resin, molded to form a soft voice prosthesis body valve or disc and then cured. The silicone parts were tested in solution proportional to their size.

30 Cytotoxicity testing was performed on various concentrations of silver oxide and silicone elastomer, and on various combinations of bodies and valves. MEM (Minimum Essential Medium) Elution and Agarose Overlay tests were done. It was decided that the most applicable test, given the use of the voice prosthesis, is the MEM test, as it tends to be more sensitive. The Agarose overlay test is useful to help determine comparative degrees of toxicity for the different percentages of silver oxide.

## TESTS PERFORMED

MATERIALAGAROSE OVERLAYMEM

5      **14% Ag<sub>2</sub>O**Q7-4750 w/14% Ag<sub>2</sub>O (valves)      Nontoxic10     MATERIALAGAROSE OVERLAYMEM15     **10% Ag<sub>2</sub>O**10% Ag<sub>2</sub>O sample discs      Toxic  
10% Silver sample discs      NontoxicQ7-4750 w/10% Ag<sub>2</sub>O (10 units)      Nontoxic

Q7-4750 w/10% silver (10 units)      Nontoxic

Q7-4750 w/10% Ag<sub>2</sub>O (valves)      NontoxicQ7-4750 w/10% Ag<sub>2</sub>O (bodies)      ToxicQ7-4750 body w/10% Ag<sub>2</sub>O valve      Nontoxic1.0% Ag<sub>2</sub>O bodies/10.0% valves      Intermediate0.5% Ag<sub>2</sub>O bodies/10.0% valves      Nontoxic20     **8% Ag<sub>2</sub>O**0.5% Ag<sub>2</sub>O bodies/8.0% valves      Nontoxic25     **5% Ag<sub>2</sub>O**Q7-4750 body w/5% Ag<sub>2</sub>O valve      Nontoxic  
Q7-4750 w/5% Ag<sub>2</sub>O (bodies)      Toxic30     **2% Ag<sub>2</sub>O**Q7-4750 w/2% Ag<sub>2</sub>O (bodies)      Toxic      Intermediate35     **0.5% Ag<sub>2</sub>O**Q7-4750 w/0.5% Ag<sub>2</sub>O (bodies)      Nontoxic      Nontoxic40     **2% Gentian Violet**

Q7-4750 w/2% Gentian violet (discs)      Toxic

45     **2% Copper Oxide**

Q7-4750 bodies w/2% Copper Oxide valves      Nontoxic      Nontoxic

**Q7-4750 control**

Q7-4750 bodies w/2% Copper Oxide valves      Nontoxic

50     The tests showed that 10% silver oxide could be used in the valves if the bodies were straight silicone elastomer, or contain a very low percentage of silver oxide. However, the 10% silver oxide valves seems to be the upper end of toxicity.

The bodies and valves at 10% showed different results. They were tested in solution proportional to their size

5 (theoretically), yet the bodies consistently showed a more toxic response than the valves. A theory is that the bodies simply had a greater mass even when this was compensated for in choosing the solution size, so more silver oxide was able to leach out into the test medium.

10 Based on these tests, in-vitro test discs were prepared using 5% and 10% silver oxide concentrations, and the clinical voice prostheses units were prepared using 10% silver oxide valves.

15 Eight tests were performed using valves of different materials to test for measurable zones of inhibition. Sample discs were prepared of the various materials in the concentrations to be tested. The silver oxide, silver, copper, copper oxide, metallic copper, and gentian violet materials were mixed with silicone elastomer, in the concentrations listed. The SPIRE silver (SPIRE A and B), SPIRE Titanium, SPIRE copper were coatings on the valve using SPIRE's coating method. The novatran is a parylene coating and the BSI is a polyacrylamide coating, both done on the valves.

20 25 Cultures of *Candida albicans* were grown up for each test date. The *Candida* cultures were swabbed onto media plates and the sample discs were placed on the plates. The plates were incubated at the specified controlled temperature for 15-24 hours and the plates read for inhibition zones. The plates were then returned to the incubator until overgrown.

30 All tests were performed under the Class 100 laminar flow bench. Particle counting was performed on the clean bench prior to initiation of the testing.

35 Summary: Measurable zones of inhibition were demonstrated only on silver oxide, in both the 5% and the 10% concentrations, and on the 2% gentian violet. The zones of inhibition were consistently in the range of 5-7mm around the test disc.

#### TESTING PERFORMED

1.

<u>Test Samples</u>	<u>Inhibition</u>
10% Ag <sub>2</sub> O	Yes

5      5%  $\text{Ag}_2\text{O}$               Yes  
10% silver  
5% silver  
Novatran  
BSI  
10     Q7-4750 (control)

2.

15     Test Samples      Inhibition  
New 10%  $\text{Ag}_2\text{O}$       Yes  
Old 10%  $\text{Ag}_2\text{O}$       Yes  
New 6% silver  
Q7-4750 (control)  
Old 10% silver xx  
20     xx Old  $\text{Ag}_2\text{O}$  was taken from a  
bottle past the expiration date

3.

25     Test Samples\*      Inhibition  
 $\text{Ag}_2\text{O}$  soaked  
in saline 1 week      Yes  
SPIRE A  
SPIRE B  
30     \*Candida successfully rinsed off  
 $\text{Ag}_2\text{O}$  sample, but not off SPIRE  
samples

4.

35     Test Samples\*      Inhibition  
0.5%  $\text{Ag}_2\text{O}$   
1.0%  $\text{Ag}_2\text{O}$   
5%  $\text{Ag}_2\text{O}$   
40     Q7-4750 (control)  
10%  $\text{Ag}_2\text{O}$   
\*No inhibition; dilutions done incorrectly.

45     (SPIRE A is a very hydrophilic surface with moderately smooth  
surface; SPIRE B is a moderate improvement in surface energy with  
a very smooth surface)

5.

Test Samples      Inhibition

5% Cu  
2% Cu  
1% Cu  
10% Ag<sub>2</sub>O      Yes  
Q7-4750 (control)  
5% Ag<sub>2</sub>O, soaked  
in saline for 18 weeks  
0.5% Ag<sub>2</sub>O

6.

Test Samples      Inhibition

No data recorded (when lab accident occurred)

7.

Test Samples      Inhibition

10% Ag<sub>2</sub>O      Yes  
2% copper oxide  
SPIRE Ti  
SPIRE Cu  
5% Metallic Cu  
Domed valve, Q7-4750

8.

Test Samples      Inhibition

2% Gentian violet      Yes  
SPIRE gold  
SPIRE Titanium  
Q7-4750 (control)

Based on the cytotoxicity information and the results of the in-vitro tests, it was decided that the clinical units of the silicone elastomer bodies and 10% silver oxide valves, and SPIRE-coated bodies with 10% silver oxide valves would be clinically tested.

Ten patients were given the clinical units under supervision.

STUDY RESULTS					
	<u>Patient Number</u>	<u>Control Time</u>	<u>Clinical Unit Time</u>	<u>Increase</u>	<u>Device</u>
10	1	8 days 27 days	49 days 36 days	41 days 9 days	10% Ag <sub>2</sub> O SPIRE-coated Ag <sub>2</sub> O
	2	59 days 36 days	127 days	68 days	10% Ag <sub>2</sub> O
15	3	28 days	69 days 215+ days	41 days 187 days	10% Ag <sub>2</sub> O 10% Ag <sub>2</sub> O
	4	22 days	258+ days	236 days	SPIRE-coated
20	5	35 days	42 days 61 days	7 days 26 days	10% Ag <sub>2</sub> O
	6	42 days 42 days	13 days 33 days 38 days	-29 days -9 days -4 days	10% Ag <sub>2</sub> O 10% Ag <sub>2</sub> O 10% Ag <sub>2</sub> O
25	7		26 days 4 days 10 days		10% Ag <sub>2</sub> O Ag <sub>2</sub> O valve/ SPIRE SPIRE-coated
	8		222 days		10% Ag <sub>2</sub> O
30	9		296 days		10% Ag <sub>2</sub> O
	10		98 days 287+ days		10% Ag <sub>2</sub> O 10% Ag <sub>2</sub> O

The 27 day sample used by patient #1 had the body SPI-Silicone coated to change its surface characteristics and the valve was silver oxide. Patient #4 used a voice prosthesis which had the body SPI-Silicone coated. Patients #8, #9 and #10 used voice prosthesis with standard silicone bodies and 10% concentration silver oxide valves.

Organic antimicrobial are preferred since they are more readily and evenly dispersed in resin in amounts usually from 0.2 to 5 percent by weight.

5

Preferred percentages of additives:

Triclosan 0.25 to 2.0 %

Butyl paraben 0.25 to 1.0 %

10

Methods of introduction:

There are three main methods of introduction of organic additives into the silicone elastomer material. The first method is simply mixing or milling the additives as a powder into silicone elastomer. This is done to either part of a two-part silicone elastomer system or to both parts together prior to molding. The problem with this method is the complete dispersion of the additive in the silicone.

The second method of introduction of the additive into silicone is to pre-dissolve the additive in a minimal amount of isopropanol or other appropriate solvent. This liquid mixture is then mixed or milled into the silicone as described above. The advantage to this method is that there is better dispersion of the additive within the silicone. One disadvantage is that it has been found that the addition of isopropanol negatively affects the physical properties of the finished, cured silicone. These effects are proportional to the amount of isopropanol added and can be minimized to negligible by the addition of only the minimal required isopropanol.

The third method is preferred as it allows dispersion of the additive throughout the silicone without the use of a solvent. This method is simply heating the additive above its melting temperature, but not past the decomposition temperature. It is then mixed into half of the two part silicone at this temperature. The silicone is allowed to cool prior to mixing both parts together and molding. This method provides a uniform distribution of additive throughout the silicone matrix.

5

Toxicity testing:

Triclosan:

<u>Test</u>	<u>Results</u>
Cytotoxicity (MEM Elution) on the valve material alone	Toxic
Cytotoxicity (MEM Elution) on the device with valve material	Nontoxic
Acute Oral Toxicity (7 day observation in the mouse)	Nontoxic

10

15

Butyl Paraben

<u>Test</u>	<u>Results</u>
Cytotoxicity (MEM Elution) on the device with valve material	Nontoxic
Acute Oral Toxicity (7 day observation in the mouse)	Nontoxic

20

100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%

## 5 Zone of Inhibition Data

## Preface:

10 In each of these cases, unless noted, a sample of silicone with respective additive was punched from a slab. The final dimensions of the sample pieces were roughly 5 mm in diameter by 2 mm thick. Each variation of these samples were placed separately in 0.45 saline solution and incubated at 37°C. At the specified time, a sample was taken out of the solution and evaluated for zone of inhibition.

15 In each of the cases below, the testing organisms was *Candida albicans*, ATCC 10231. The medium used was Sabouraud Dextrose agar. Incubation time was 18 to 24 hours at 37°C. The zone of inhibition test was performed per internal testing standards of Helix Medical, Inc. The base material was Nusil MED 20 4940 silicone.

25 The zone of inhibition test technically measures leachability of an antimicrobial from a test article. The samples are placed on a lawn of microbial organisms of choice. As the substance leaches from the test sample, there is a concentration gradient set up as a function diffusion through the sample and diffusion away from the sample. At a certain concentration, a critical concentration, the growth of 30 microorganisms will be greatly reduced. This is manifest as no growth or greatly reduced growth in a radius around the sample. With the purpose of the invention in mind, the size of the zone 35 of inhibition is relatively unimportant, as long as the longevity of the substance with some microbial activity is maintained over time in a soaking condition. The result chosen to signify acceptable antimicrobial activity is inhibition of microbial growth underneath the sample. This signifies that the concentration at the surface of the sample has retained at least the critical concentration of antimicrobial substance. If the surface concentration can be maintained at or above the critical

5 concentration, then little to no growth will colonize on the  
 surface of this material.

10 Note: For inhibition underneath sample, it is measured either as  
 Inhibition (I), Partial Inhibition (PI), or No Inhibition (NI).

Triclosan 0.5%:

Time Soaked (weeks)	Zone of Inhibition (mm)	Inhibition Underneath Sample (I, PI, NI)
1 day	0	I
1	0	I
2	0	I
3	0	I
4	0	I
12	0	I
16	0	I

Triclosan 1.0%:

Time Soaked (weeks)	Zone of Inhibition (mm)	Inhibition Underneath Sample (I, PI, NI)
1 day	1	I
1	1	I
2	1	I
3	1	I
4	1	I
8	1	I
12	1	I
16	0.5	I

## Triclosan 2.0%:

Time Soaked (weeks)	Zone of Inhibition (mm)	Inhibition Underneath Sample (I, PI, NI)
1 Day	1	I
1	1	I
2	1	I
3	1	I
11	1	I
12	1	I
16	1	I
20	1	I
24	1	I

## Triclosan 2.0% molded valves:

Time Soaked (weeks)	Zone of Inhibition (mm)	Inhibition Underneath Sample (I, PI, NI)
1 day	1	I
1	1	I
2	1	I
3	1	I
4	1	I
8	1	I

## Butyl paraben 1%:

Time Soaked (weeks)	Zone of Inhibition (mm)	Inhibition Underneath Sample (I, PI, NI)
1 Day	1.5	I
1	1.5	I
2	1.5	I
3	2	I
4	2	I
8	2	I
12	1	I
16	1	I

## Butyl Paraben 1% molded valves:

Time Soaked (weeks)	Zone of Inhibition (mm)	Inhibition Underneath Sample (I, PI, NI)
1 Day	0	I
1	0	I
2	0	I
3	0	I
4	0	I
8	0	PI

Voice prosthesis formed with microbial resistant valves will be able to be used for much longer periods without the need to remove the prosthesis for cleaning. The prosthesis can be made with thinner valves, body and flanges since there is no need to be as stiff and rigid to avoid bending and wrinkling due to growth of *Candida Albicans*. The body of the voice prosthesis can also be compounded with antimicrobial agents at a level acceptable to the FDA.

The Indwelling Low Pressure Voice Prosthesis of the invention is designed for those persons who are unable or resistant to changing the voice prosthesis every two or three days as was recommended for the non-indwelling, patient-removable Low Pressure Voice Prosthesis. The Indwelling Low Pressure Voice Prosthesis has been specifically designed to maintain the placement of the prosthesis in the tracheoesophageal puncture so that routine changing of the device is not necessary.

It is to be realized that only preferred embodiments of the invention have been described and that numerous substitutions, modifications and alterations are permissible without departing from the spirit and scope of the invention as defined in the following claims.